GoodRx Holdings Inc. said Monday it has teamed up with Novo Nordisk A/S to sell the Danish drugmaker’s GLP-1 injectables Ozempic and Wegovy to self-paying U.S. patients for $499 a month. The discounted offer, available immediately through the GoodRx platform, covers all strengths of both semaglutide pens and can be redeemed at more than 70,000 retail pharmacies nationwide. The companies say the program marks the first time Ozempic has been offered to cash-pay customers at that price. Interest in GLP-1 therapies continues to swell: GoodRx recorded about 17 million searches for the drug class over the past 12 months, a 22% increase from the prior year, underscoring persistent gaps in insurance coverage for weight-loss and diabetes treatments. “Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,” GoodRx President and Chief Executive Officer Wendy Barnes said in a statement. Dave Moore, Novo Nordisk’s executive vice president for U.S. operations, called the initiative an “unprecedented” opportunity to broaden access to the company’s FDA-approved medicines. Investors cheered the deal. GoodRx shares surged as much as 35% in early U.S. trading, their biggest intraday gain since 2023, while Novo Nordisk shares also advanced in Copenhagen. The partnership gives GoodRx a new foothold in the fast-growing GLP-1 market and expands Novo Nordisk’s reach among patients who pay out of pocket.